Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
NCT07671560Phase 4Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 4 trial of ensartinib, anlotinib in non-small cell lung cancer (NSCLC). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ensartinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07671560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671560.